Prostaglandin E pathway (PGE pathway)

The Prostaglandin E (PGE) pathway is a critical lipid signaling cascade centered on the synthesis and action of Prostaglandin E2 (PGE2), a key mediator of diverse physiological and pathological processes (StatPearls, 2023). The pathway begins with the release of arachidonic acid from cell membranes, which is converted by cyclooxygenase enzymes (COX-1 and COX-2) into prostaglandin H2, and subsequently into PGE2 by specific prostaglandin E synthases like mPGES-1 (UniProt, 2024). PGE2 exerts its biological effects by binding to four distinct G protein-coupled receptors, designated EP1 through EP4, which are distributed across various tissues (PubMed, 2022). This pathway is a primary driver of inflammation, pain (nociception), and fever, while also playing essential roles in gastric mucosal protection, renal function, and reproduction (NIH, 2023). Pharmacological modulation of the PGE pathway is a cornerstone of modern medicine, primarily through the use of nonsteroidal anti-inflammatory drugs (NSAIDs) that inhibit COX enzymes to reduce PGE2 production. Additionally, specific EP receptor agonists and antagonists are utilized for applications ranging from labor induction to the treatment of inflammatory conditions. Dysregulation of the PGE pathway is heavily implicated in chronic inflammatory diseases and the progression of various cancers, where it promotes tumor cell survival and immune evasion (Nature Reviews Drug Discovery, 2017).

Other names

PGE2 signaling pathwayProstanoid E2 pathwayCOX-2/mPGES-1/EP receptor axis

Inhibition of cyclooxygenase enzymes (COX-1/COX-2) to reduce PGE2 synthesis; agonism or antagonism of E-type prostanoid (EP) receptors to modulate downstream signaling pathways including cAMP and calcium signaling.